XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Key result
In a real-world population of patients with non-valvular atrial fibrillation, rivaroxaban use was associated with low rates of major bleeding (2.1/100 pt-yrs) and stroke (0.7/100 pt-yrs).
Population
6,784 patients with non-valvular atrial fibrillation, mean age 71.5 years, 41% female, multinational.
Design
Cohort
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
May inform real-world expectations for rivaroxaban in NVAF; extends trial data yet remains hypothesis-generating.
Study Design
Type
Observational (n=6,784)
Multicenter
Yes
Structured PICO
P
Population
6,784 patients with non-valvular atrial fibrillation (NVAF), mean age 71.5 years, 41% female, multinational (Europe, Israel, Canada).
I
Intervention
Rivaroxaban newly started in routine clinical use, mean treatment duration 329 days.
O
Outcome
Major outcomes including major bleeding, symptomatic thromboembolic events (stroke, systemic embolism, transient ischaemic attack, and myocardial infarction), and all-cause death.hard clinical
In a large, real-world, prospective observational study, rivaroxaban was associated with low rates of stroke and major bleeding in unselected patients with non-valvular atrial fibrillation.
Cite This Study
Camm et al. (2015) conducted an observational in non-valvular atrial fibrillation (NVAF) (n=6,784). rivaroxaban was evaluated on major bleeding. In a real-world population of patients with non-valvular atrial fibrillation, rivaroxaban use was associated with low rates of major bleeding (2.1/100 pt-yrs) and stroke (0.7/100 pt-yrs).